Mesoblast's licensee Takeda (Alofisel®) appears to score a big win in Spanish Covid-19 trial, page-2

Yes this is ancient news from April, which we discussed at the time. Don't understand why the Daily Mail is recycling it now~

The Spainish have moved on to a larger trial https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001266-11/ES for which I have not seen any news.

Although as per https://hotcopper.com.au/posts/44731514/single Adipose derived treatments may be less ideal than Bone Marrow derived due to

AT-derived MSCs are among the highly TF/CD142-expressing cell products, and careful dose-escalation by TiGenix/Takeda in their SPECELL study (AT-MSCs Cx611 product) has shown a significant increase in the coagulation activation markers thrombin-antithrombin-complex (TAT) and D-dimer for infusion of 4 million cells/kg vs. controls in healthy volunteers with normal coagulation parameters (75). Accordingly, the dose-limiting toxicity should be lower in hypercoagulable COVID-19 patients, potentially limiting the cell dose to <4 million cells/kg.